Technion scientists have developed a novel method for rapid and accurate sensing of coronavirus without the need to rely on PCR amplification, a technique that makes millions or even billions of copies of DNA so that there is enough material to test. The new technique can identify the presence of SARS-CoV-2 in a sample by counting and quantifying the virus’ RNA molecules with single-molecule precision. This method is not biased by PCR amplification errors, allowing researchers to develop a more accurate clinical diagnostic technique. Researchers have also found that the technique can be used to detect metastatic cancer.
Article published at ats.org on October 21, 2020.
The research was led by Professor Amit Meller and carried out by researchers Dr. Yana Rozevsky, Dr. Tal Gilboa, Dr. Xander van Kooten, and staff scientist Dr. Diana Huttner — all of whom are researchers in the Faculty of Biomedical Engineering — and Professor Ulrike Stein and Dr. Dennis Kobelt from the Max Delbrück Center for Molecular Medicine and the Charité Hospital in Berlin.
Illustration of DNA molecules passing through a nanopore one after the other
The most widely used test for COVID-19 is the RT-qPCR test. It requires first collecting a sample from a patient using a swab, “opening” the virus, and extracting RNA from it. In the next stage, called reverse transcription (RT), specific ‘target’ RNA sequences are copied to the DNA form. Finally, this DNA is amplified by a polymerase chain reaction (PCR). Millions of copies are made so that enough DNA is present to be detected, finally leading to a diagnosis for COVID-19.
RT-qPCR testing requires large quantities of special reagents, expensive laboratory equipment, and highly trained professionals. Recent studies have also shown that test results can change from one day to the next and that the massive amplification process can generate significant errors. For these reasons, worldwide efforts are being devoted to developing faster, more affordable, and more accurate tests. This task is particularly challenging in cases where the “viral load” (the amount of viral RNA) in a sample is low and can evade sensing.
Professor Amit Meller
Faculty of Biomedical Engineering
Using Nanopores to “Sense” COVID-19 and Metastatic Cancer
The new method presented by Prof. Meller’s research group relies on original technologies that the lab has developed in the past two decades, using nanofabricated holes (so-called “nanopores”) to sense single biological molecules. The effectiveness of this technology has already been demonstrated in a number of other biomedical uses.
Unlike conventional molecular diagnostics, which require large volumes of samples containing millions of copies of the same molecule, nanopore sensing analyzes individual biological molecules from much smaller samples. A strong electrical field is used to unfold and thread individual DNA molecules through the nanoscopic hole containing electrical or optical sensors. Each molecule that passes through the hole gives a characteristic “signature,” which enables identification and immediate counting of the molecules. This approach opens up the possibility of miniaturising the diagnostic systems while improving the accuracy and reliability of tests.
In an article recently published in ACS Nano, the researchers present two applications of their new method: identifying RNA molecules that signal the emergence of metastatic cancer and detecting coronavirus RNA.
In the first application, the researchers demonstrated the method’s potential for early detection of metastatic cancer by quantifying the levels of MACC1 — one of the primary genes known to signal the formation of a metastatic state. Thanks to its high degree of sensitivity, the new technique successfully quantified the gene’s expression in cancerous cells at the early stages of illness (known as stages I and II) — a challenge that PCR-based technologies failed to meet. Needless to say, the earlier these genetic biomarkers are discovered, the better the chances of successful treatment.
In the second application, the researchers detected the RNA molecules of the SARS-CoV-2 virus using the same approach. Unlike other tests, the new approach avoids introducing “noise” and errors into the system, obtaining a more precise and accurate analysis method.
Commercializing the Technology
With further work, the nanopore sensing system is expected to become a portable device that will make cumbersome lab equipment unnecessary. Technological and clinical research is continuing at the Technion Faculty of Biomedical Engineering, in collaboration with the BioBank at the Rambam Health Care Campus. At the same time, steps are being taken to commercialize the technology in order to make it available for general use as soon as possible.